West Pharmaceutical Services 관리

관리 기준 확인 3/4

West Pharmaceutical Services CEO는 Eric Green, Apr2015 에 임명되었습니다 의 임기는 9.58 년입니다. 총 연간 보상은 $ 9.40M, 12.1% 로 구성됩니다. 12.1% 급여 및 87.9% 보너스(회사 주식 및 옵션 포함). 는 € 47.71M 가치에 해당하는 회사 주식의 0.23% 직접 소유합니다. 47.71M. 경영진과 이사회의 평균 재임 기간은 각각 4.5 년과 9.5 년입니다.

주요 정보

Eric Green

최고 경영자

US$9.4m

총 보상

CEO 급여 비율	12.1%
CEO 임기	9.6yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	9.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Eric Green 의 보수는 West Pharmaceutical Services 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$500m
Jun 30 2024	n/a	n/a	US$525m
Mar 31 2024	n/a	n/a	US$569m
Dec 31 2023	US$9m	US$1m	US$593m
Sep 30 2023	n/a	n/a	US$559m
Jun 30 2023	n/a	n/a	US$519m
Mar 31 2023	n/a	n/a	US$552m
Dec 31 2022	US$8m	US$1m	US$586m
Sep 30 2022	n/a	n/a	US$631m
Jun 30 2022	n/a	n/a	US$686m
Mar 31 2022	n/a	n/a	US$684m
Dec 31 2021	US$9m	US$1m	US$662m
Sep 30 2021	n/a	n/a	US$613m
Jun 30 2021	n/a	n/a	US$519m
Mar 31 2021	n/a	n/a	US$423m
Dec 31 2020	US$8m	US$989k	US$346m
Sep 30 2020	n/a	n/a	US$312m
Jun 30 2020	n/a	n/a	US$286m
Mar 31 2020	n/a	n/a	US$261m
Dec 31 2019	US$7m	US$936k	US$242m
Sep 30 2019	n/a	n/a	US$230m
Jun 30 2019	n/a	n/a	US$229m
Mar 31 2019	n/a	n/a	US$219m
Dec 31 2018	US$5m	US$880k	US$207m
Sep 30 2018	n/a	n/a	US$155m
Jun 30 2018	n/a	n/a	US$151m
Mar 31 2018	n/a	n/a	US$133m
Dec 31 2017	US$5m	US$824k	US$151m

보상 대 시장: Eric 의 총 보상 ($USD 9.40M )은 German 시장( $USD 5.20M ).

보상과 수익: Eric 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Eric Green (54 yo)

9.6yrs

테뉴어

US$9,395,896

보상

Mr. Eric M. Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President...

리더십 팀

이름	위치	테뉴어	보상	소유권
Eric Green	Non-Independent Chair of the Board	9.6yrs	US$9.40m	0.23% € 47.7m
Bernard Birkett	Senior VP & CFO	6.4yrs	US$3.64m	0.0095% € 2.0m
Silji Abraham	Senior VP & CTO	3.9yrs	US$1.67m	0.0040% € 812.9k
Kimberly MacKay	Senior VP	3.9yrs	US$1.49m	0.0019% € 386.9k
Cindy Reiss-Clark	Senior VP & Chief Commercial Officer	5yrs	US$1.53m	0.0067% € 1.4m
Chad Winters	VP, Chief Accounting Officer & Corporate Controller	5.1yrs	데이터 없음	0.0018% € 372.5k
John Sweeney	Head of Investor Relations	no data	데이터 없음	데이터 없음
Michele Polinsky	Vice President of Global Communications	no data	데이터 없음	데이터 없음
Rudy Poussot	Senior VP of Strategy & Corporate Development	less than a year	데이터 없음	데이터 없음
Annette Favorite	Chief Human Resources Officer & Senior VP	9.1yrs	US$1.14m	0.0090% € 1.8m
Kathy DePadua	Senior VP and Chief Quality & Regulatory Officer	2.5yrs	데이터 없음	데이터 없음
Aileen Ruff-Patry	President of Contract Manufacturing	less than a year	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: WPS 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Eric Green	Non-Independent Chair of the Board	9.5yrs	US$9.40m	0.23% € 47.7m
Myla Lai-Goldman	Independent Director	10.8yrs	US$359.35k	0.024% € 4.9m
Robert Friel	Independent Director	4.8yrs	US$330.66k	0.0034% € 691.5k
Thomas Hofmann	Independent Director	17.1yrs	US$390.35k	0.059% € 12.2m
Mark Buthman	Independent Director	13.8yrs	US$378.23k	0.056% € 11.5m
Douglas Michels	Independent Director	13.8yrs	US$377.01k	0.059% € 12.2m
Paolo Pucci	Lead Independent Director	8.2yrs	US$367.44k	0.012% € 2.5m
Stephen Lockhart	Independent Director	2.3yrs	US$331.46k	0.0015% € 304.6k
William Feehery	Independent Director	12.8yrs	US$362.83k	0.040% € 8.3m
Deborah L. Keller	Independent Director	7.4yrs	US$333.45k	데이터 없음
Morihiro Sudo	Honorary Director	no data	데이터 없음	데이터 없음
Molly Joseph	Independent Director	3.3yrs	US$321.43k	0.00087% € 179.0k

9.5yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: WPS 의 이사회는 경험(평균 재직 기간 9.5 년)으로 간주됩니다.

West Pharmaceutical Services 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

West Pharmaceutical Services, Inc. Announces Resignation of Silji Abraham as Senior Vice President & Chief Technology Officer, Effective December 31, 2024

Insufficient new directors

Bernard Birkett No Longer Have Principal Operating Officer Position of West Pharmaceutical Services, Inc

West Pharmaceutical Services, Inc., Annual General Meeting, Apr 23, 2024

Independent Director recently sold €404k worth of stock

Key Executive recently sold €4.7m worth of stock

Recent updates

Third quarter dividend of US$0.21 announced

Third quarter 2024 earnings released: EPS: US$1.87 (vs US$2.17 in 3Q 2023)

West Pharmaceutical Services, Inc. Raises Earnings Guidance for the Full Year 2024

West Pharmaceutical Services, Inc. to Report Q3, 2024 Results on Oct 24, 2024

West Pharmaceutical Services, Inc. Announces Resignation of Silji Abraham as Senior Vice President & Chief Technology Officer, Effective December 31, 2024

Insufficient new directors

Second quarter 2024 earnings released: EPS: US$1.53 (vs US$2.09 in 2Q 2023)

Upcoming dividend of US$0.20 per share

West Pharmaceutical Services, Inc. to Report Q2, 2024 Results on Jul 25, 2024

West Pharmaceutical Services, Inc. Introduces Daikyo Crystal Zenith® Ready-to-Use Nested Vials in Tub at the International Society for Cell and Gene Therapy

Dividend of US$0.20 announced

Bernard Birkett No Longer Have Principal Operating Officer Position of West Pharmaceutical Services, Inc

West Pharmaceutical Services, Inc. Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$1.57 (vs US$1.88 in 1Q 2023)

Upcoming dividend of US$0.20 per share

West Pharmaceutical Services, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

West Pharmaceutical Services, Inc., Annual General Meeting, Apr 23, 2024

Fourth quarter dividend of US$0.20 announced

West Pharmaceutical Services, Inc. Announces Second Quarter 2024 Dividend, Payable on May 1, 2024

Full year 2023 earnings released: EPS: US$7.99 (vs US$7.88 in FY 2022)

Investor sentiment deteriorates as stock falls 18%

West Pharmaceutical Services, Inc. Provides Earnings Guidance for the Full Year 2024

West Pharmaceutical Services, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Upcoming dividend of US$0.20 per share at 0.2% yield

West Pharmaceutical Services, Inc. Announces Dividend for the First Quarter of 2024, Payable on February 7, 2024

West Pharmaceutical Services, Inc. Receives FDA 510(K) Clearance for Vial2bag Advanced 13mm Admixture Device

Upcoming dividend of US$0.20 per share at 0.3% yield

West Pharmaceutical Services, Inc. Approves Fourth-Quarter 2023 Dividend, Payable on November 15, 2023

Third quarter 2023 earnings released: EPS: US$2.17 (vs US$1.62 in 3Q 2022)

West Pharmaceutical Services, Inc. to Report Q3, 2023 Results on Oct 26, 2023

West Pharmaceutical Services, Inc. Revises Earnings Guidance for the Full-Year 2023

Second quarter 2023 earnings released: EPS: US$2.09 (vs US$2.53 in 2Q 2022)

Upcoming dividend of US$0.19 per share at 0.2% yield

West Pharmaceutical Services, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Independent Director recently sold €404k worth of stock

First quarter 2023 earnings released: EPS: US$1.88 (vs US$2.34 in 1Q 2022)

Upcoming dividend of US$0.19 per share at 0.2% yield

Full year 2022 earnings released: EPS: US$7.88 (vs US$8.90 in FY 2021)

West Pharmaceutical Services, Inc. (NYSE:WST) announces an Equity Buyback for $1,000 million worth of its shares.

West Pharmaceutical Services, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Upcoming dividend of US$0.19 per share

West Pharmaceutical Services, Inc. Approves First-Quarter 2023 Dividend, Payable on February 1, 2023

Upcoming dividend of US$0.19 per share

Third quarter 2022 earnings released: EPS: US$1.62 (vs US$2.37 in 3Q 2021)

West Pharmaceutical Services, Inc. Updating Full-Year 2022 Guidance

West Pharmaceutical Services, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Key Executive recently sold €4.7m worth of stock

Second quarter 2022 earnings released: EPS: US$2.53 (vs US$2.53 in 2Q 2021)

West Pharmaceutical Services, Inc. Provides Earnings Guidance for the Full Year 2022

West Pharmaceutical Services, Inc. Elects Stephen Lockhart as New Director to the Board

West Pharmaceutical Services, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Upcoming dividend of US$0.18 per share

West Pharmaceutical Services, Inc. Introduces Daikyo Crystal Zenith 2.25mL Insert Needle Syringe System At BIO International Convention

West Pharmaceutical Services, Inc. Announces Executive Leadership Appointments

First quarter 2022 earnings released: EPS: US$2.34 (vs US$2.05 in 1Q 2021)

West Pharmaceutical Services, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Upcoming dividend of US$0.18 per share

West Pharmaceutical Services, Inc. Announces Board Changes

West Pharmaceutical Services, Inc. Announces Second-Quarter 2022 Dividend, Payable on May 4, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

West Pharmaceutical Services, Inc. Announces Asset Impairment for the Fourth Quarter Ended December 31, 2021

West Pharmaceutical Services, Inc. to Report Q4, 2021 Results on Feb 17, 2022

Upcoming dividend of US$0.18 per share

Upcoming dividend of US$0.18 per share

Second quarter 2021 earnings released: EPS US$2.53 (vs US$1.24 in 2Q 2020)

Upcoming dividend of US$0.17 per share

Senior VP & Chief Technology Officer recently sold €598k worth of stock